<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>World Pharma Today</title>
	<atom:link href="https://www.worldpharmatoday.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 09 Jun 2026 12:44:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>World Pharma Today</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>SK Biopharmaceuticals Opens LinX Hub for Korean Biotech</title>
		<link>https://www.worldpharmatoday.com/news/sk-biopharmaceuticals-opens-linx-hub-for-korean-biotech/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 12:44:06 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/sk-biopharmaceuticals-opens-linx-hub-for-korean-biotech/</guid>

					<description><![CDATA[<p>SK Biopharmaceuticals has established a new innovation platform in the United States aimed at helping Korean biotechnology and pharmaceutical companies expand their presence in international markets. The company announced Monday that it officially opened SK Life Science LinX at its subsidiary, SK Life Science, in New Jersey during a ceremony held last week. The initiative [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/sk-biopharmaceuticals-opens-linx-hub-for-korean-biotech/">SK Biopharmaceuticals Opens LinX Hub for Korean Biotech</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position</title>
		<link>https://www.worldpharmatoday.com/news/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:58:55 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Acquisition]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/</guid>

					<description><![CDATA[<p>GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/">GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery</title>
		<link>https://www.worldpharmatoday.com/news/sanofi-and-owkin-partner-to-co-develop-agentic-ai-tools-for-drug-discovery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:54:12 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/sanofi-and-owkin-partner-to-co-develop-agentic-ai-tools-for-drug-discovery/</guid>

					<description><![CDATA[<p>Sanofi has entered into a multi-year agreement with France-based agentic AI company Owkin to jointly develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin&#8217;s K Pro platform, an advanced AI system designed to augment drug discovery and development across pharmaceutical workflows. The two companies have maintained a working relationship since 2021, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/sanofi-and-owkin-partner-to-co-develop-agentic-ai-tools-for-drug-discovery/">Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Boehringer&#8217;s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial</title>
		<link>https://www.worldpharmatoday.com/news/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:45:56 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/</guid>

					<description><![CDATA[<p>German pharmaceutical company Boehringer Ingelheim has reported that its experimental obesity drug, survodutide, significantly reduced visceral abdominal fat and liver fat while largely preserving lean body mass in a late-stage clinical study. The data strengthens the company&#8217;s argument that the drug offers meaningful health benefits beyond overall weight loss percentage a distinction that analysts have [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/boehringers-survodutide-cuts-visceral-and-liver-fat-while-preserving-lean-mass-in-late-stage-trial/">Boehringer’s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Living with CLL: Understanding Targeted Therapy for CLL and Its Impact</title>
		<link>https://www.worldpharmatoday.com/news/living-with-cll-understanding-targeted-therapy-for-cll-and-its-impact/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:21:22 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/living-with-cll-understanding-targeted-therapy-for-cll-and-its-impact/</guid>

					<description><![CDATA[<p>Introduction Chronic Lymphocytic Leukemia (CLL) is the most common blood cancer in adults. It develops when there is an accumulation of atypical lymphocytes, which are a type of white blood cell in the blood, bone marrow, and lymphatic tissue. Although in many cases CLL grows very slowly as compared to other blood cancers, it can [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/living-with-cll-understanding-targeted-therapy-for-cll-and-its-impact/">Living with CLL: Understanding Targeted Therapy for CLL and Its Impact</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CytomX and Regeneron Expand Bispecific Cancer Therapy Collaboration with New Targets</title>
		<link>https://www.worldpharmatoday.com/news/cytomx-and-regeneron-expand-bispecific-cancer-therapy-collaboration-with-new-targets/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 06 Jun 2026 08:25:33 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cytomx-and-regeneron-expand-bispecific-cancer-therapy-collaboration-with-new-targets/</guid>

					<description><![CDATA[<p>CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their ongoing research collaboration focused on developing tumor-activated bispecific cancer therapy candidates, broadening the scope of an agreement that was originally established in 2019. The expanded collaboration introduces additional bispecific targets into the partnership framework and significantly increases the potential milestone and royalty payments available under the deal. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/cytomx-and-regeneron-expand-bispecific-cancer-therapy-collaboration-with-new-targets/">CytomX and Regeneron Expand Bispecific Cancer Therapy Collaboration with New Targets</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Pfizer and Chai Discovery Sign AI Licensing Deal to Accelerate Drug Discovery</title>
		<link>https://www.worldpharmatoday.com/news/pfizer-and-chai-discovery-sign-ai-licensing-deal-to-accelerate-drug-discovery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 06 Jun 2026 08:04:24 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<category><![CDATA[Pfizer]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/pfizer-and-chai-discovery-sign-ai-licensing-deal-to-accelerate-drug-discovery/</guid>

					<description><![CDATA[<p>Pfizer has entered into a licensing agreement with Chai Discovery, granting the pharmaceutical giant access to Chai&#8217;s generative AI platform for integration into its drug discovery operations. The deal provides Pfizer with early access to the newly revealed Chai-3 model, as well as a dedicated model trained specifically on Pfizer&#8217;s proprietary data and workflows — [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/pfizer-and-chai-discovery-sign-ai-licensing-deal-to-accelerate-drug-discovery/">Pfizer and Chai Discovery Sign AI Licensing Deal to Accelerate Drug Discovery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Eli Lilly Genetic Medicine Push Expands with Ascidian Deal</title>
		<link>https://www.worldpharmatoday.com/news/eli-lilly-genetic-medicine-push-expands-with-ascidian-deal/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 05 Jun 2026 13:28:49 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/eli-lilly-genetic-medicine-push-expands-with-ascidian-deal/</guid>

					<description><![CDATA[<p>Eli Lilly has entered into a research collaboration with Ascidian Therapeutics aimed at discovering and developing treatments for kidney diseases, marking another step in the company’s ongoing genetic medicine strategy. The agreement, which could be worth up to $1.9bn for the Massachusetts-based biotechnology company, will initially focus on therapies targeting kidney disorders linked to a single [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/eli-lilly-genetic-medicine-push-expands-with-ascidian-deal/">Eli Lilly Genetic Medicine Push Expands with Ascidian Deal</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CPHI Americas Relocates to Miami to Strengthen Global Industry Connectivity</title>
		<link>https://www.worldpharmatoday.com/press-releases/cphi-americas-relocates-to-miami-to-strengthen-global-industry-connectivity/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 04 Jun 2026 09:43:13 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cphi-americas-relocates-to-miami-to-strengthen-global-industry-connectivity/</guid>

					<description><![CDATA[<p>Informa Markets has announced that CPHI Americas will relocate to Miami in 2027, marking a significant step in the event’s ongoing development as a platform for pharmaceutical innovation, outsourcing and strategic partnerships. Scheduled for May 25-26, 2027, at the Miami Convention Center, the move is intended to improve international accessibility, encourage greater executive participation and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/cphi-americas-relocates-to-miami-to-strengthen-global-industry-connectivity/">CPHI Americas Relocates to Miami to Strengthen Global Industry Connectivity</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Sanofi and Snowflake Team Up to Deploy AI-Powered Field Agent Support Tool</title>
		<link>https://www.worldpharmatoday.com/news/sanofi-and-snowflake-team-up-to-deploy-ai-powered-field-agent-support-tool/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 04 Jun 2026 08:02:55 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/sanofi-and-snowflake-team-up-to-deploy-ai-powered-field-agent-support-tool/</guid>

					<description><![CDATA[<p>Sanofi has partnered with cloud data platform company Snowflake to develop an artificial intelligence-driven tool designed to assist the pharmaceutical giant&#8217;s field sales representatives in their day-to-day operations. The collaboration aims to give Sanofi&#8217;s field agents faster, more efficient access to business-critical data and insights while they are out in the field, reducing time spent [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/sanofi-and-snowflake-team-up-to-deploy-ai-powered-field-agent-support-tool/">Sanofi and Snowflake Team Up to Deploy AI-Powered Field Agent Support Tool</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
